The development of in-silico trials is an international scale challenge. The European Commission strongly promotes reduction of animal testing and human trials, as evidenced by several Horizon 2020 calls in Health Societal challenge.
A French university is building a consortium to propose in-silico trials based on a novel 3D-digital and physiological model of the liver perfusion to test the injection of drugs for the treatment of hepatic diseases. This will help medical doctors to plan protocols faster and better, as they will benefit from a computerized prediction of the effect of one or several drugs on a patient, before employing it practically.
The project requires a high multi-disciplinarity including:
- ICT : computer vision, medical image processing, digital geometry.
- Medicine: clinical practice, hepatology, hepatic surgery.
- Chemistry, Physiology: identification of optimal parameters for the in-silico trial, assessment of drug delivery and action
-Economics: Estimates of benefits for human health (and animal welfare), cost-effectiveness and cost-utility modeling.
The consortium is looking for public or private partners specialized in medico-economic studies with decision-making tools aimed at optimizing the use of 3D-model of the liver perfusion and in-silico trial model as well as evaluating the economic impacts in terms of health outcomes at a population level.
The project will be submitted on the H2020 Personalised Medicine programme SC1-PM-16-2017 call which has a deadline 14 March 2017, 17h.
The deadline for expression of interest is January 27th.
The consortium is looking for public or private partners specialized in medico-economic studies with decision-making tools aimed at optimizing the use of 3D-model of the liver perfusion and in-silico trial model as well as evaluating the economic impacts in terms of health outcomes at a population level.
Type of partners: research and academic institutions , private companies
Specific area: medico-economic evaluation
- Strategic guidance and recommendations for cost-effectiveness studies, and for quantification of benefits for human health (and animal welfare)
- Development of budget impact models.